文献速递肾癌与肾肿瘤

慢性肾脏病在局部晚期肾细胞癌中更常见

Chronic Kidney Disease Is More Common in Locally Advanced Renal Cell Carcinoma.
PubMed 文献 · Urology · 2017-03-30

该回顾性研究评估肾细胞癌(RCC)患者慢性肾脏病(CKD)的临床预测因素。1569例接受肾切除术的患者中,45%术前存在中度及以上CKD;临床T3/T4期患者高危比例高于T2和T1期(39.5% vs 22%和19%,P = .0001);临床肿瘤分期和性别是蛋白尿、低肾小球滤过率及高CKD风险组的独立预测因素。

要点

  • 1569例肾皮质肿瘤手术患者中,45%术前存在中度及以上慢性肾脏病。
  • 临床T3/T4期患者CKD高危比例高于T2和T1期(39.5% vs 22%和19%,P = .0001)。
  • 临床肿瘤分期和性别是蛋白尿、低肾小球滤过率及高CKD风险组的预测因素。

核心结论

  • 45%的肾细胞癌患者在治疗前存在中度及以上慢性肾脏病。
  • 治疗前慢性肾脏病与局部晚期肾细胞癌(cT3/T4)呈正相关。
  • 这种关联可能与肿瘤增大或分期增高导致功能性肾实质丢失增加有关,对患者管理有重要意义。

研究设计与样本

  • 回顾性研究,查询Spectrum Health和University of California, San Diego的机构登记数据,纳入1569例接受根治性或部分性肾切除术的肾皮质肿瘤患者,术前记录肾小球滤过率和蛋白尿状态。

主要发现

  • 慢性肾脏病风险低危860例(55%)、中度升高381例(24%)、高危194例(12%)、极高危134例(9%)。
  • 临床T3/T4期患者高危比例高于T2和T1期(39.5% vs 22%和19%,P = .0001)。
  • 增加的半径、外生或内生属性、肿瘤距集合系统或肾窦的毫米距离、前或后位置、相对于极线的位置评分、肿瘤大小和临床肿瘤分期与基线CKD风险增加强相关。
  • 临床肿瘤分期和性别是单因素和多因素分析中蛋白尿、较低肾小球滤过率和较高CKD风险组的唯一预测因素。

关键数值与推荐

  • 蛋白尿分级:A1(<30 mg)、A2(30-300 mg)、A3(>300 mg)。
  • 慢性肾脏病按肾脏疾病改善全球预后分类分为低、中度升高、高危、极高危。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To retrospectively evaluate clinical predictors of chronic kidney disease (CKD) in renal cell carcinoma (RCC) patients to identify associations between patient- and tumor-specific factors with poorer renal function. CKD and RCC are interrelated, with 26%-44% of RCC patients having concomitant CKD at diagnosis. PATIENTS AND METHODS: Institutional registries from Spectrum Health and University of California, San Diego, were queried for preoperative glomerular filtration rate and proteinuria status before radical or partial nephrectomy. Preoperative clinical and tumor factors were recorded; proteinuria was classified as A1 (<30 mg), A2 (30-300 mg), and A3 (>300 mg). CKD was grouped by Kidney Disease Improving Global Outcomes classification (low, moderately increased, high, very high). RESULTS: We evaluated 1569 patients undergoing surgery for renal cortical tumors. CKD status was low risk in 860 (55%), moderately increased in 381 (24%), high in 194 (12%), and very high in 134 (9%) patients. Increased radius, exophytic or endophytic properties, nearness of tumor to the collecting system or sinus in millimeters, anterior or posterior, location relative to polar lines score, tumor size, and clinical tumor stage were strongly associated with increased CKD risk at baseline. Clinical stage T3/T4 disease had more at-risk patients than stages T2 and T1 disease (39.5% vs 22% and 19%, P = .0001). Clinical tumor stage and gender were the only predictors of proteinuria, lower glomerular filtration rate, and higher CKD risk group in both univariate and multivariate analyses. CONCLUSION: Forty-five percent of patients with RCC had moderate or higher CKD before treatment. A positive correlation between pretreatment CKD and locally advanced RCC (cT3/T4) was present. This likely relates to increased loss of functional parenchyma with increasing tumor size or stage, with important implications in patient management.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Dey S, Hamilton Z, Noyes SL, et al. Chronic Kidney Disease Is More Common in Locally Advanced Renal Cell Carcinoma. Urology. 2017. PMID: 28365357. doi:10.1016/j.urology.2017.03.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。